Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the “Purchase Agreement”) with Blue Harbour Asset Management L.L.C-FZ (“Blue Harbour”), it has completed a private placement of the Company’s newly designated Series B Convertible Preferred Stock (the “Preferred Stock”). Pursuant to the Purchase Agreement, Blue Harbour purchased 100,000 shares of Preferred Stock for an ...
Occidental and 1PointFive Secure Class VI Permits for STRATOS Direct Air Capture Facility HOUSTON, April 07, 2025 (GLOBE NEWSWIRE) -- Occidental (NYSE: OXY) and its subsidiary 1PointFive today announced that the U.S Environmental Protection Agency approved its Class VI permits to sequester carbon dioxide (CO2) captured from STRATOS when the world’s largest Direct Air Capture (DAC) facility begins operating in Ector County, Texas. The permits, the first issued to sequester CO2 from a DAC project, allows Occidental to leverage its expertise managing large quantities of CO2 while advancing t...
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth PALO ALTO, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Leone Patterson to its Board of Directors and as Chair of the Board’s Audit Committee. “We’re delighted to...
Occidental to Announce First Quarter Results Wednesday, May 7, 2025; Hold Conference Call Thursday, May 8, 2025 HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- (NYSE: OXY) will announce its first quarter 2025 financial results after close of market on Wednesday, May 7, 2025, and will hold a conference call to discuss the results on Thursday, May 8, 2025, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (international callers dial 1-412-317-5417) or via webcast at Participants may pre-register for the conference call at . First quarter 2025 f...
Occidental Announces Results of Offer to Exercise Warrants at a Temporarily Reduced Price HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced the results of its offer to exercise Occidental’s outstanding publicly traded warrants (the “Warrants”) at a temporarily reduced price of $21.30 per Warrant (the “Offer”). The Offer expired at 5:00 p.m. Eastern Time on March 31, 2025. Based on the final count by Equiniti Trust Company, LLC, the depositary agent for the Offer, 41,941,075 Warrants were tendered and not validly withdrawn (including 69,166 Warrants tendered pursuan...
Kalaris Announces Closing of Merger with AlloVir Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina Currently enrolling nAMD patients in a Phase 1 trial, with initial data from Part 1 of the trial expected in the second half of 2025 Post-transaction cash of approximately $100 million expected to fund operations into the fourth quarter of 2026 Shares expected to trade on Nasdaq under “KLRS”, effective March 19, 2025 ...
Kalaris and AlloVir Announce Stockholder Approval of Merger Combined company expected to trade on Nasdaq under “KLRS” after closing PALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent diseases of the retina, and AlloVir, Inc. (Nasdaq: ALVR) announced today the results for the proposals voted upon by AlloVir stockholders at a Special Meeting of Stockholders held on March 12, 2025. The AlloVir stockholders ...
Occidental Announces Offer to Exercise Warrants at a Temporarily Reduced Price HOUSTON, March 03, 2025 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced an offer to exercise its outstanding publicly traded warrants (the “Warrants”) at a temporarily reduced price (the “Offer”). The Offer is available to holders of the Warrants, each representing the right to purchase one share of Occidental’s common stock, $0.20 par value per share, at an exercise price of $22.00. The Warrants were initially distributed by Occidental on August 3, 2020 in the form of a dividend to the holders of record of O...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.